Mural Oncology Set to Showcase Research at SITC Annual Meeting
Mural Oncology Set to Showcase Research at SITC Annual Meeting
Mural Oncology plc (NASDAQ: MURA), a pioneering company focused on immuno-oncology, is gearing up for a significant event—the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This important gathering will take place from November 6-10, 2024, in Houston, Texas. Mural Oncology is excited to announce they will be presenting key insights into their innovative therapies aimed at addressing critical cancer treatment challenges.
Presentations Highlighting Cutting-Edge Research
At the event, Mural Oncology plans to showcase three impactful poster presentations. The first presentation will delve into pharmacodynamic data derived from the phase 1/2 ARTISTRY-3 study, which explores less frequent dosing of nemvaleukin, their engineered interleukin-2 therapy. This research is essential, as it aims to provide deeper insight into the tumor microenvironment and how treatment with nemvaleukin can be optimized.
Details of Upcoming Presentations
Here are the specific details about the presentations Mural Oncology will be sharing at the SITC:
Tumor Microenvironment Study
Title: Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Abstract Number: 217
Presentation Date: Friday, Nov. 8
IL-18 and IL-12 Research Findings
Title: Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Abstract Number: 1340
Presentation Date: Saturday, Nov. 9
Title: Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits
Abstract Number: 1300
Presentation Date: Saturday, Nov. 9
About Mural Oncology
Mural Oncology is utilizing its advanced protein engineering platform to create innovative immunotherapies for cancer. With an emphasis on developing cytokine therapies, the company aims to provide meaningful benefits to patients facing various types of cancer. Their lead candidate, nemvaleukin, is currently involved in trials for platinum-resistant ovarian cancer and mucosal melanoma, with results expected in the near future.
The Functionality of Nemvaleukin
Nemvaleukin is engineered to enhance the anti-tumor properties of the interleukin-2 (IL-2) pathway without the side effects commonly associated with traditional treatments. It specifically interacts with the intermediate-affinity IL-2 receptor, promoting the growth of CD8+ T cells and natural killer cells, essential for mounting effective immune responses against tumors, while minimizing the unwanted expansion of regulatory T cells.
Exploring IL-18 and IL-12 Programs
Mural Oncology is also making strides in its IL-18 program, which aims to overcome limitations posed by IL-18 binding protein, a decoy receptor that hinders the efficacy of native IL-18. Through innovative protein engineering techniques, they are working to enhance the stability and potency of IL-18.
Furthermore, the IL-12 program is equally crucial. By reformulating IL-12 into separate inactive components, Mural Oncology seeks to deliver powerful anti-cancer effects while avoiding systemic toxicity. This revolutionary approach could change how IL-12 therapies are administered and ultimately improve patient outcomes.
Contact Mural Oncology for Inquiries
If you have further questions or require more information about Mural Oncology and its programs, please reach out to:
Katie Sullivan
Email: katie.sullivan@muraloncology.com
Frequently Asked Questions
What is Mural Oncology known for?
Mural Oncology is recognized for developing innovative cytokine-based immunotherapies aimed at improving cancer treatment outcomes.
What will Mural Oncology present at the SITC meeting?
The company will present data from its ARTISTRY-3 study and findings on its IL-18 and IL-12 programs.
Why is nemvaleukin significant?
Nemvaleukin is engineered to enhance immune responses against tumors while minimizing adverse side effects, representing a promising treatment option for patients.
What is the purpose of the IL-18 program?
The IL-18 program aims to enhance the efficacy and durability of IL-18, making it more effective in stimulating immune responses against cancer.
How can I learn more about Mural Oncology?
Visit Mural Oncology's official website or contact them directly for additional information on their research and development initiatives.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Supreme Court Denies Banker Calk's Appeal Linked to Manafort
- Scilex Secures $50 Million Financing to Strengthen Growth Potential
- Nissan Takes Major Step with ChargeScape Investment Strategy
- North Korea Moves to Amend Constitution Amid Regional Tensions
- Top Insider Trades: Insights into Recent Market Moves
- Possibility of Increasing Stakes in Japanese Gaming Sector
- JD.com: Navigating Growth Amid China's Stimulus Wave
- seqWell Launches Innovative LongPlex Kit for DNA Sequencing
- Celebrating Community Champions: 2024 Good Neighbor Award Winners
- Thompson Thrift Celebrates Opening of Premier at West Park
Recent Articles
- Latest Findings on GT-02287 Present Promising Parkinson's Disease Treatment
- NIU Technologies Unveils KQi 100F Scooter at Electrify Expo
- AerCap's Impressive Aircraft Leasing Growth in 2024
- Orchard and Er-Kim Expand Libmeldy Availability Across Regions
- Rio Tinto's Strategic Move into Arcadium Lithium Sparks Interest
- Discover Top Health Care Stocks with Impressive Dividends
- Capital Square's Strategic Move Yields Impressive Returns
- Welltower Plans Third Quarter Earnings Release and Call
- Investors' Opportunity to Join Paragon 28 Class Action Lawsuit
- Laser Photonics Expands Operations with New State-of-the-Art Facility
- Metagenomi Investors Urged to Join Class Action Lawsuit Now
- RedMane Unveils Enhanced mCase Features for Better Service Delivery
- Introducing ecozy's New Commercial Ice Makers for All Needs
- RCG Global Services Strengthens Offerings with Aethereus Deal
- Major Brokerages Predict 25 Bps Rate Cuts from Fed in November
- Top Financial Stocks Positioned for Innovation in the Coming Years
- Jim Rickards' Essential Strategies for Wealth Protection Amid Chaos
- Alliance Trust PLC Reports Latest Net Asset Values for Investors
- Oatly Group Prepares to Announce Q3 2024 Financial Insights
- CytoMed Therapeutics Advances CAR-T Trials with Major Grant
- Exciting Launch of Charlotte’s Web CBD Gummies in Canada
- Microbix Unveils Innovative HSV Control Solution at EMMD
- Beasley Broadcast Group Completes Note Exchange Successfully
- AIRSUPRA® Significantly Lowers Severe Asthma Risks in Trials
- Exploring New Frontiers in Cancer Therapy with UNO
- Billionaires Target High-Growth FAANG Stocks for Success
- Marti Technologies Launches Ride-Hailing Monetization Strategy
- Unveiling the Potential of GT-02287 in Parkinson's Research
- Discover Top ETFs for Smart Investment Strategies
- Bruker Unveils OptoVolt for Enhanced Neuroscience Research
- InspireMD's Innovative CGuard Study Receives FDA Approval
- Cleveland-Cliffs Hosts Key Government Officials for Steel Industry
- Mural Oncology Showcases Innovations in Immuno-Oncology Research
- ViiV Healthcare Expands Access to Long-Acting HIV Prevention
- Foremost Clean Energy Partners with Denison Mines for Uranium Exploration
- Judo Bio Advances Gene Therapy Research for Kidney Treatment
- Chris Akrimi's New Role at NuORDER by Lightspeed Enhances Growth
- GXO Logistics Plans Earnings Call for Third Quarter 2024
- Oak Hill Bio Welcomes New Executive Leadership and Board Members
- Perspective Therapeutics Engages in Key Oncology Events Ahead
- Energy Recovery Announces Upcoming Financial Results and Webinar
- Generations Bancorp NY, Inc. Joins OTCQX for Enhanced Trading
- Consensus Cloud Solutions Plans Exciting Q3 Earnings Call
- Gray Media Expands Reach with New Local News Live Apps
- BPGbio Teams with Oxford University to Propel Protein Research Forward
- Rubicon Organics Unveils Comprehensive Sustainability Report
- Scholar Rock Celebrates Phase 3 Success for SMA Treatment
- NIU Technologies Unveils KQi 100F Electric Scooter at Expo
- Judo Bio Marks $100M Financing and Welcomes Rajiv Patni as CEO
- Virios and Wex Join Forces to Launch Dogwood Therapeutics